Development of vascularized adipose organoids from PBMSCs and their application in evaluating Celastrol's effects.
Li S., Kan F., Ji S., Cao D., Liu H., Wu J.
Laboratory Study, published in Adipocyte (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Adipocyte (2025)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40878808
- DOI
- 10.1080/21623945.2025.2548787
Abstract (original English)
Obesity lacks physiologically relevant human models, which constrains in-depth investigation into its underlying mechanisms and hampers the development of effective therapeutic strategies for obesity and its associated comorbidities. Here, we developed vascularized adipose organoids (VAOs) from peripheral blood mesenchymal stem cells (PBMSCs) using a standardized three-dimensional dynamic culture system that sequentially induces angiogenesis and adipogenesis. These VAOs mimic native adipose tissue with coexisting adipocytes and endothelial cells. Transcriptomic analysis shows that vascularization alters genes linked to inflammation and redox homoeostasis, yielding distinct metabolic and inflammatory profiles in VAOs versus non-vascularized controls. Notably, upon TNF-α stimulation, VAOs exhibit markedly reduced IL-6 secretion relative to non-vascularized adipose organoids (NVAOs). Importantly, Celastrol simultaneously inhibits angiogenesis and adipogenesis in VAOs and broadly modulates the expression of genes associated with mitochondrial metabolic processes. This study establishes PBMSC-derived VAOs as a scalable, patient-accessible model for investigating adipose development, metabolism, and inflammation. The system also provides a platform for mechanistic research and high-throughput drug screening in obesity and related metabolic diseases.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.